Saturday 17 October 2026
Export VINC’s income statement to Excel — free account
Vincerx Pharma, Inc.
VINC Healthcare Biotechnology
In the quarter to March 2025, EPS grew 87.9% and free cash flow grew 42.5%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
0.02
0.01
−33.33%
Follow VINC
Vincerx Pharma, Inc. (VINC) P/E ratio
Vincerx Pharma, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR compare | n/m |
| VRPX Virpax Pharmaceuticals, Inc. compare | n/m |
| CDT CDT Equity Inc. compare | n/m |
| VINC Vincerx Pharma, Inc. | n/m |
| ATXI Avenue Therapeutics, Inc. compare | n/m |
| SEELQ Seelos Therapeutics, Inc. compare | n/m |
| EFTR eFFECTOR Therapeutics, Inc. compare | n/m |
| CERO CERo Therapeutics Holdings, Inc. compare | 0.0× |
| SCNI Scinai Immunotherapeutics Ltd. Sponsored ADR compare | 0.0× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)